Analyst Rating Update on Ironwood Pharmaceuticals (IRWD)

Ironwood Pharmaceuticals (IRWD) : Zacks Investment Research ranks Ironwood Pharmaceuticals (IRWD) as 2, which is a Buy recommendation. 4 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. A total of 4 analysts believe that the stock has a limited upside, hence they advise a Hold. The average broker rating of 8 research analysts is 2, which indicates as a Buy.

Ironwood Pharmaceuticals (IRWD) : The consensus price target for Ironwood Pharmaceuticals (IRWD) is $14.14 for the short term with a standard deviation of $5.05. The most optimist securities analyst among the 7 who monitor the stock believes that the stock can reach $24, however, the pessimist price target for the company is $10.

Company shares have received an average consensus rating of Hold for the current week


Ironwood Pharmaceuticals (NASDAQ:IRWD): During Wednesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $13.75 and $13.68 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $14.26. The buying momentum continued till the end and the stock did not give up its gains. It closed at $14.24, notching a gain of 2.96% for the day. The total traded volume was 990,957 . The stock had closed at $13.83 on the previous day.

Ironwood Pharmaceuticals, Inc. is a pharmaceutical company. The Company has a product, linaclotide, which is available in the United States and Mexico under the brand name LINZESS, and is available in European countries and Canada under the brand name CONSTELLA. Linaclotide is also being developed and commercialized in other parts of the world by certain of its partners. Linaclotide provides patients and healthcare practitioners with a treatment option for adults in the United States and certain other countries with irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC) and gastrointestinal (GI) disorders. The Company in collaboration with Astellas Pharma Inc. (Astellas) is developing linaclotide for the treatment of patients with IBS-C.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *